Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TPSAB1 | Q15661 | 2/20 | 0.43 |
| ▸ | TPSD1 | Q9BZJ3 | 2/20 | 0.43 |
| ▸ | TPSG1 | Q9NRR2 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 3/20 | 0.41 |
| ▸ | SYK | P43405 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.38 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7267095 | 0.92 | POLB (0.45) | POLBSYKMAPTTDP1KDM4E | |
| SCHEMBL11639032 | 0.92 | CTRB1 (0.39) | POLBMAPTTDP1ITGB3ITGA2B | |
| SCHEMBL4891567 | 0.88 | TDP1 (0.33) | TPSAB1TPSD1TPSG1POLBMAPT | |
| SCHEMBL6833631 | 0.88 | TDP1 (0.33) | TPSAB1TPSD1TPSG1POLBMAPT | |
| SCHEMBL9748132 | 0.85 | L3MBTL1 (0.43) | MAPTTDP1ITGB3ITGA2BMAPK1 | |
| Water SCHEMBL11367764 | 0.85 | ITGB3 (0.35) | POLBITGB3ITGA2B | |
| SCHEMBL18076338 | 0.84 | TPSAB1 (0.47) | TPSAB1TPSD1TPSG1SYKITGB3 | |
| SCHEMBL7196919 | 0.83 | L3MBTL1 (0.39) | POLBSYKMAPTTDP1 | |
| SCHEMBL2133987 | 0.83 | MDM2 (0.38) | TPSAB1TPSD1TPSG1 | |
| SCHEMBL22610140 | 0.83 | MDM2 (0.38) | TPSAB1TPSD1TPSG1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250031699-A1 | Method for Controlling Parasitic Plants | AJINOMOTO CO., INC. (JP) | 2025-01-30 | — | — | US | disclosed |
| EP-0309566-B1 | STLV-III-RELATED POLYPEPTIDES, DIAGNOSTIC SYSTEMS AND ASSAY METHODS | JOHNSON & JOHNSON (US) | 1994-01-12 | — | — | EP | disclosed |
| EP-0495877-A1 | METHODS AND COMPOSITIONS FOR HEALING BONE. | PROCYTE CORP (US) | 1992-07-29 | — | — | EP | disclosed |
| WO-1991005797-A1 | METHODS AND COMPOSITIONS FOR HEALING BONE | PROCYTE CORPORATION (US) | 1991-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250031699-A1 | Method for Controlling Parasitic Plants | PTMS, DAO, GNMT | TPSAB1 4040/4885TPSD1 3019/4885TPSG1 2307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.